Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GBT440 Extension Study in Sickle Cell Disease
NCT03041909Phase 2Completed
- Sponsor
- Global Blood Therapeutics
- Start
- Aug 2016
- Primary completion
- Jun 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of voxelotor in sickle cell disease (SCD), sponsored by Global Blood Therapeutics. Started Aug 2016; status: completed.
02
Drugs
voxelotor
03
Conditions
sickle cell disease (SCD)
Beyond the preview
Go deeper on NCT03041909.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03041909.